Diyabet komplikasyonlarında ileri glikasyon son ürünleri

Diabetes mellitus ileri evrede mikrovasküler ve makrovasküler komplikasyonlarla karşımıza çıkan metabolik bir hastalıktır. Yüksek glukoz konsantrasyonlarında dolaşımdaki veya dokulardaki proteinlerin non-enzimatik glikasyonu ile ileri glikasyon son ürünlerinin oluştuğu bilinmektedir. İleri glikasyon son ürünleri hücrenin yapısını, fonksiyonunu değiştirirler ve sitokinler ile büyüme faktörlerinin sentezine ve salınımına sebep olurlar. Böylece ileri glikasyon son ürünleri diyabetin mikrovasküler ve makrovasküler komplikasyonlarının gelişimine katkı sağlarlar.İleri glikasyon inhibisyonunun nefropati, retinopati ve nöropati gibi diyabet komplikasyonlarını azaltıcı etkileri saptanmıştır. İleri glikasyon son ürünlerinin oluşumunun ve birikiminin tedavisinde kullanılan bazı ajanlar bu derlemede özetlenmiştir.

Advanced glycation end-products in complications of diabetes mellitus

Diabetes mellitus is a metabolic disease, which results in microvascular and macrovascular complications in later stages. It has been known that with elevated glucose concentrations, proteins in both the circulation and the tissues are non-enzymatically glycated and this results in the production of advanced glycation end-products. Advanced glycation end-products alter cell structure and function which lead to the synthesis and release of cytokines and growth factors. Therefore, advanced glycation end-products contribute to the microvascular and macrovascular complications of diabetes mellitus. Inhibition of advanced glycation was found to reduce diabetic complications such as nephropathy, retinopathy and neuropathy. Some of the agents that are used for the treatment of advanced glycation end-products formation and accumulation are summarized in this review.

PDF

___

1. American Diabetes Association (ADA). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2011;34:S62-9. doi:10.2337/dc11-S062
2. Nessar A. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005;67: 3–21. doi:10.1016/j.diabres.2004.09.004
3. Singh R, Barden A, Mori T, et al. Advanced glycation end-products: A review. Diabetologia 2001;44:129-46. doi:10.1007/s001250051591
4. Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol (Paris) 2006;54:405-19. doi:10.1016/j.patbio.2006.07.006
5. Turk Z. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiol Res 2010;59: 147-56.
6. Huebschmann AG, Vlassara H, Regensteıner JG, et al. Diabetes and advanced glycoxidation end products. Diabetes Care 2006;29:1420-32. doi:10.2337/dc05-2096
7. Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006;114:597-605. doi:10.1161/CIRCULATIONAHA. 106.621854
8. Bierhaus A, Hofmann MA, Ziegler R, et al. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37:586-600. doi:10.1016/S0008-6363(97)00233-2
9. Schmidt AM, Yan SD, Yan SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55. doi:10.1172/JCI14002
10. Ding Q, Keller JN. Evaluation of RAGE isoforms, ligands and signaling in the brain. Biochim Biophys Acta 2005;1746:18-27. doi:10.1016/ j.bbamcr.2005.08.006
11. Lapolla A, Traldi P, Fedele D. Importance of measuring products of non-enzymatic glycation of proteins. Clin Biochem 2005; 38:103- 15. doi:10.1016/j.clinbiochem.2004.09.007
12. Chibber R, Molinatti PA, Rosatto N, et al. Toxic action of advanced glycation endproducts on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia 1997; 40:156-64. doi:10.1007/s001250050657
13. Yamagashi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011;46: 217-24. doi:10.1016/j.exger.2010.11.007
14. Tanaka N, Yonekura H, Yamagishi S, et al. The receptor for advanced glycation endproducts is induced by the glycation products themselves and tumour necrosis factor-a through nuclear factor-kB, and by 17 b-estradiol through Sp-1 in human vascular endothelial cells, J. Biol Chem 2000;275:25781–90. doi:10.1074/jbc.M001235200
15. Bucala R, Makita Z, Vega G, et al. Modification of LDL by advanced glycation endproducts contribute to the dyslipidaemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441-5. doi:10.1073/pnas.91.20.9441
16. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL and impaired HDL receptor mediated cholesterol efflux. Diabetes 1991;40:377-84. doi:10.2337/diabetes.40.3.377
17. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009;46: 83-106. doi:10.1080/10408360802610878
18. Sugiyama S, Miyata T, Horie K, et al. Advanced glycation endproducts in diabetic nephropathy. Nephrol Dial Transplant 1996;11:91-4.
19. Schrijvers BF, Flyvbjerg A, Tilton RG. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 2005;21:324-39. doi:10.1093/ndt/gfi217
20. De Vriese, AS, Tilton RG, Elger, M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993-1000.
21. Vlassara H, Brownlee M, Cerami A, Recognition and uptake of human diabetic peripheral nerve myelin by macrophages. Diabetes 1985;34:553–7. doi:10.2337/diabetes.34.6.553
22. Goh SY, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008 93:1143-52. doi:10.1210/jc.2007-1817
23. Ueno H, Koyama H, Tanaka S, et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 2008;57:1452-7. doi:10.1016/j.metabol.2008.05.016
24. Chabroux S, Canouï-Poitrine F, Reffet S, et al. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Diabetes Metab 2010;36:152-7.
25. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27:535- 42. doi:10.1046/j.1529-8027.2002.02011_16.x
26. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003; 419:31-40. doi:10.1016/j.abb.2003.08.013
27. Schalkwijk CG. Therapeutic interventions in the glyc(oxid)ation pathway. Immunol Endocr Metab Agents Med Chem 2007;7:57-68.
28. Gogas Yavuz D, Ersöz HÖ, Tuncel M, et al. Effects of aminoguanidine on glomerular basement membrane thickness and anionic charge in a diabetic rat model. Int J Exp Diabetes Res 2001;2:225–32. doi: 10.1155/EDR.2001.225
29. Gogas Yavuz D, Bozkurt S, Aydın H, et al. Effects of aminoguanidine on dermal collagen structure and TGF-beta expression in streptozotocin induced diabetic rats. Marmara Med J 2005;18;76-80.
30. Gogas Yavuz D, Küçükkaya B, Ersöz HÖ, et al. Effects of aminoguanidine on lipid and protein oxidation in diabetic rat kidneys. Int J Exp Diabetes Res 2002;3:145-51. doi: 10.1080/15604280214487
31. Daroux M, Prevost G, Maillard-Lefebvre H. Advanced glycation end-products: Implications for diabetic and non-diabetic nephropathies. Diabetes Metab 2010;36:1-10. doi:10.1016/j.diabet. 2009.06.005
32. Kaur H, Prabhakar S. Novel therapies of diabetic nephropathy. Nephrology Reviews 2011; 3:e4:23-35. doi:10.4081/nr.2011.e4
33. Cheng G, Wang LL, Long L, et al. Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats. Br J Pharmacol 2007;152: 1196-1206. doi:10.1038/sj.bjp.0707533
34. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocindiabetic rat. Kidney Int 2002;61:939-50. doi:10.1046/j.1523- 1755.2002.00207.x
35. Stitt A, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002;51:2826-32. doi:10.2337/diabetes.51.9.2826
36. Cooper ME, Thallas V, Forbes J, et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000;43:660–4. doi:10.1007/ s001250051355
37. Goova MT, Kislinger JLT, Bucciarelli WLG, et al. Blockade of receptors for advanced glycation endproducts restores effective wound healing in diabetic mice, Am J Pathol 2001;159:513–25. doi:10.1016/S0002-9440(10)61723-3
38. Yamagishi S, Nakamura K, Matsui T, et al. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. Med Hypotheses 2007;69:666-8. doi:10.1016/j.mehy.2006.12.045
39. Beisswenger PJ, Howell SK, Touchette AD, et al. Metformin Reduces Systemic Methylglyoxal Levels in Type 2 Diabetes. Diabetes 1999;48:198-202. doi:10.2337/diabetes.48.1.198
40. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-9. doi:10.1038/nm834
41. Babaei-Jadidi R, Karachalias N, Ahmed N, et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003;52:2110-20. doi:10.2337/diabetes.52.8.2110